Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postoperative EGFR-TKI Therapy for High-Risk Synchronous Resectable Contralateral Pulmonary Nodules in Patients With EGFR-Mutant Non-Small Cell Lung Cancer（ARMOR2501）

NCT06924398 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06924398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postoperative EGFR-TKI Therapy for High-Risk Synchronous Resectable Contralateral Pulmonary Nodules in Patients With EGFR-Mutant Non-Small Cell Lung Cancer（ARMOR2501）
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2025
Completion date
December 31, 2025
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)